Arthur Przybyl - ANI Pharmaceuticals Insider

ANIP -- USA Stock  

USD 54.38  0.40  0.74%

  CEO
Mr. Arthur S. Przybyl is President, Chief Executive Officer, Director of the Company
Age: 60  CEO Since 2013      
218-634-3500  http://www.anipharmaceuticals.com
Przybyl is an experienced healthcare executive in a career that spans over 25 years and includes the management of both specialty pharmaceutical and medical device companies. From August 2002 through January 2009, Mr. Przybyl served as President and Chief Executive Officer of Akorn, Inc., a NASDAQlisted specialty pharmaceutical company that manufactures and markets ophthalmic, liquid and lyophilized injectable, and vaccine drug products. Prior to Akorn, Mr. Przybyl was President of privatelyheld company Hearing Innovations, Inc. and President and Chief Operating Officer of NASDAQlisted company Bioject, Inc., both of which are medical device companies. During his career, Mr. Przybyl has held several sales and marketing management positions, including Senior Vice President, Sales and Marketing for International Medication Systems, Inc. and Director, Corporationrationrationrate Marketing and National Accounts for LyphoMed, Inc., both specialty pharmaceutical companies.

Arthur Przybyl Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 6.67 % which means that it generated profit of $6.67 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 0.07 % meaning that it created $0.07 on every $100 dollars invested by stockholders.
The company currently holds 204.61 M in liabilities with Debt to Equity (D/E) ratio of 110.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. ANI Pharmaceuticals has Current Ratio of 3.76 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 5 records

CEO Since

Ting ZhengChina Cord Blood Corporation
2017
Eddie GrayDynavax Technologies Corporatio
2013
Rui ArashiyamaChina Cord Blood Corporation
N/A
Yue DengChina Cord Blood Corporation
N/A
Barry SimonNantKwest
2017

Entity Summary

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota. ANI Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 173 people.ANI Pharmaceuticals (ANIP) is traded on BATS Exchange in USA. It is located in MINNESOTA U.S.A and employs 173 people. ANI Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

ANI Pharmaceuticals Leadership Team

Robert Brown, Chairman of the Board
David Nash, Independent Director
Charlotte Arnold, CFO, Vice President
Mark Ginski, Vice President of Corticotropin Product Development
Robert Schrepfer, VP of New Bus. Devel. and Contract Manufacturing
Daniel Raynor, Director
Stephen Carey, CFO, Vice President
David Sullivan, VP of Quality Operations
Karen Quinn, Vice President - Corticotropin Regulatory Affairs
Thomas Haughey, Independent Director
Patrick Walsh, Independent Director
James Marken, VP of Operations
Peter Lankau, Director
Fred Holubow, Independent Director
Tracy Marshbanks, Director
Arthur Przybyl, CEO and President and Director
Thomas Penn, Director

Stock Performance Indicators

Current Sentiment - ANIP

ANI Pharmaceuticals Investor Sentiment

Most of Macroaxis users are presently bullish on ANI Pharmaceuticals. What is your sentiment towards investing in ANI Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

ANI Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for ANI Pharmaceuticals and China Cord Blood. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Theme Ratings module to determine theme ratings based on digital equity recommendations. macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Search macroaxis.com